IL28B polymorphisms do not predict response to therapy in chronic hepatitis C with HCV genotype 5
- Nabil Antaki1,
- Stéphanie Bibert2,
- Kamel Kebbewar3,
- Fouad Asaad4,
- Osama Baroudi5,
- Sawsan Alideeb5,
- Milad Hadad6,
- Dirar Abboud1,
- Houda Sabah7,
- Pierre-Yves Bochud2,
- Francesco Negro8
- 1Department of Gastroenterology, Saint Louis Hospital, Ismailiye, Aleppo, Syria
- 2Service of Infectious Diseases, Department of Medicine, University Hospital and University of Lausanne, Lausanne, Switzerland
- 3Laboratory Medicine, Saint Louis Hospital, Ismailiye, Aleppo, Syria
- 4Department of Internal Medicine, Squelbiye National Hospital, Squelbiye, Syria
- 5Department of Gastroenterology, Damascus Hospital, Damascus, Syria
- 6Department of Gastroenterology, Ibn Nafis Hospital, Damascus, Syria
- 7Department of Laboratory Medicine, Damascus Hospital, Damascus, Syria
- 8Divisions of Gastroenterology and Hepatology and of Clinical Pathology, University Hospital, Genève, Switzerland
- Correspondence to Professor Francesco Negro, Divisions of Gastroenterology and Hepatology and of Clinical Pathology, University Hospitals, 4 rue Gabrielle-Perret-Gentil, CH-1211 Geneva 14, Switzerland; francesco.negro{at}hcuge.ch
-
Contributors NA, KK, FA, OB, SA, MH, DA and HS contributed patient samples and performed all analyses other than genetic tests; SB performed all genetic analyses; NA, P-YB and FN analysed the data and wrote the manuscript; All authors approved the manuscript.
- Accepted 12 January 2012
- Published Online First 16 February 2012
- Hepatitis C
- hepatitis B
- genetic polymorphisms
- hepatic fibrosis
- hepatocellular carcinoma
- antiviral therapy
- bile duct stones
- biliary endoscopy
- colonic polyps
- Crohn's disease
- achalasia
- acute pancreatitis
- autoimmune liver disease
- hepatitis D
- hepatitis E
- hepatitis A
We read with interest the paper by Hayes et al1 on the impact of genetic polymorphisms near IL28B in predicting treatment response in chronic hepatitis C patients infected with hepatitis C virus genotype 1 (HCV-1). These results confirm the large, existing evidence in support of single nucleotide polymorphisms (SNPs) near IL28B being the most powerful predictors of virological response in patients infected with all major HCV genotypes, that is, 1–4.2 No data is available for HCV-5, a rare genotype neglected in clinical trials.3 We report IL28B SNP frequency and its impact on treatment outcome in 49 patients of homogeneous Caucasian ancestry, all from Syria, infected with HCV-5. Treatment included …
